NASDAQ:IDRA - Idera Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.93 +0.04 (+2.12 %)
(As of 05/27/2018 03:44 PM ET)
Previous Close$1.93
Today's Range$1.88 - $1.95
52-Week Range$1.32 - $2.87
Volume947,664 shs
Average Volume1.14 million shs
Market Capitalization$419.41 million
P/E Ratio-4.60
Dividend YieldN/A
Beta2.29

About Idera Pharmaceuticals (NASDAQ:IDRA)

Idera Pharmaceuticals logoIdera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology. Its drug candidates include IMO-2125, an agonist that is in Phase III clinical trial in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma; and which is in Phase Ib monotherapy trial in multiple tumor types for the treatment of refractory solid tumors, as well as IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. The company is also developing IDRA-008 apolipoprotein C-III gene target for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; nucleic acid chemistry compound for renal target; and IMO-9200 for treating non-malignant gastrointestinal disorders. In addition, it is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GlaxoSmithKline Intellectual Property Development Limited to license, research, develop, and commercialize pharmaceutical compounds from its nucleic acid chemistry technology for the treatment of selected targets in renal disease; Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.

Receive IDRA News and Ratings via Email

Sign-up to receive the latest news and ratings for IDRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IDRA
CUSIPN/A
Phone617-679-5500

Debt

Debt-to-Equity RatioN/A
Current Ratio8.89
Quick Ratio8.89

Price-To-Earnings

Trailing P/E Ratio-4.60
Forward P/E Ratio-4.95
P/E GrowthN/A

Sales & Book Value

Annual Sales$900,000.00
Price / Sales466.01
Cash FlowN/A
Price / CashN/A
Book Value$0.46 per share
Price / Book4.20

Profitability

EPS (Most Recent Fiscal Year)($0.42)
Net Income$-65,980,000.00
Net Margins-9,117.07%
Return on Equity-82.70%
Return on Assets-73.93%

Miscellaneous

Employees62
Outstanding Shares217,310,000

Idera Pharmaceuticals (NASDAQ:IDRA) Frequently Asked Questions

What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals Inc (NASDAQ:IDRA) posted its quarterly earnings data on Wednesday, May, 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.01. The biotechnology company had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.17 million. Idera Pharmaceuticals had a negative return on equity of 82.70% and a negative net margin of 9,117.07%. View Idera Pharmaceuticals' Earnings History.

What price target have analysts set for IDRA?

2 equities research analysts have issued twelve-month price targets for Idera Pharmaceuticals' stock. Their predictions range from $4.00 to $4.00. On average, they anticipate Idera Pharmaceuticals' share price to reach $4.00 in the next year. View Analyst Ratings for Idera Pharmaceuticals.

Who are some of Idera Pharmaceuticals' key competitors?

Who are Idera Pharmaceuticals' key executives?

Idera Pharmaceuticals' management team includes the folowing people:
  • Mr. Vincent J. Milano, Pres, CEO & Director (Age 54)
  • Mr. Louis J. Arcudi III, Principal Accounting Officer, Sr. VP of Operations, CFO, Treasurer & Assistant Sec. (Age 57)
  • Dr. Jonathan Yingling, Sr. VP & Chief Scientific Officer (Age 49)
  • Mr. Robert Clayton Fletcher, Sr. VP of Bus. Devel. & Strategic Planning (Age 55)
  • Dr. Joanna C. Horobin, Sr. VP & Chief Medical Officer (Age 63)

Has Idera Pharmaceuticals been receiving favorable news coverage?

News coverage about IDRA stock has trended somewhat positive on Sunday, Accern Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Idera Pharmaceuticals earned a coverage optimism score of 0.08 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.31 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Idera Pharmaceuticals' major shareholders?

Idera Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (2.23%), Artal Group S.A. (1.27%), JPMorgan Chase & Co. (1.27%), Barclays PLC (0.21%), Wasatch Advisors Inc. (0.19%) and Schwab Charles Investment Management Inc. (0.16%). Company insiders that own Idera Pharmaceuticals stock include Bros Advisors Lp Baker, Invest Corp Pillar, Julian Baker and Maxine Gowen. View Institutional Ownership Trends for Idera Pharmaceuticals.

Which major investors are selling Idera Pharmaceuticals stock?

IDRA stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. View Insider Buying and Selling for Idera Pharmaceuticals.

Which major investors are buying Idera Pharmaceuticals stock?

IDRA stock was purchased by a variety of institutional investors in the last quarter, including Artal Group S.A., Millennium Management LLC, Barclays PLC, Wasatch Advisors Inc., Kassirer Asset Management Corp, Bluefin Trading LLC, Schwab Charles Investment Management Inc. and New York State Common Retirement Fund. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Julian Baker and Maxine Gowen. View Insider Buying and Selling for Idera Pharmaceuticals.

How do I buy shares of Idera Pharmaceuticals?

Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Idera Pharmaceuticals' stock price today?

One share of IDRA stock can currently be purchased for approximately $1.93.

How big of a company is Idera Pharmaceuticals?

Idera Pharmaceuticals has a market capitalization of $419.41 million and generates $900,000.00 in revenue each year. The biotechnology company earns $-65,980,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. Idera Pharmaceuticals employs 62 workers across the globe.

How can I contact Idera Pharmaceuticals?

Idera Pharmaceuticals' mailing address is 167 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-679-5500 or via email at [email protected]


MarketBeat Community Rating for Idera Pharmaceuticals (IDRA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  233 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  374
MarketBeat's community ratings are surveys of what our community members think about Idera Pharmaceuticals and other stocks. Vote "Outperform" if you believe IDRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Idera Pharmaceuticals (NASDAQ:IDRA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Idera Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 107.25%. The high price target for IDRA is $4.00 and the low price target for IDRA is $4.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.00$5.40$5.40
Price Target Upside: 107.25% upside98.02% upside148.85% upside172.73% upside

Idera Pharmaceuticals (NASDAQ:IDRA) Consensus Price Target History

Price Target History for Idera Pharmaceuticals (NASDAQ:IDRA)

Idera Pharmaceuticals (NASDAQ:IDRA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018HC WainwrightReiterated RatingBuy$4.00LowView Rating Details
9/12/2017Piper Jaffray CompaniesReiterated RatingBuy$4.00LowView Rating Details
4/24/2017Robert W. BairdInitiated CoverageOutperform ➝ Outperform$5.00MediumView Rating Details
4/11/2017WedbushReiterated RatingOutperform$6.00LowView Rating Details
3/22/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$8.00HighView Rating Details
11/29/2016CowenReiterated RatingOutperformN/AView Rating Details
10/7/2016S&P Equity ResearchBoost Price Target$1.86 ➝ $2.10N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Idera Pharmaceuticals (NASDAQ:IDRA) Earnings History and Estimates Chart

Earnings by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)

Idera Pharmaceuticals (NASDAQ:IDRA) Earnings Estimates

2018 EPS Consensus Estimate: ($0.37)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.09)($0.09)($0.09)
Q2 20181($0.09)($0.09)($0.09)
Q3 20181($0.09)($0.09)($0.09)
Q4 20181($0.10)($0.10)($0.10)

Idera Pharmaceuticals (NASDAQ IDRA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q1 2018($0.09)($0.10)$0.17 million$0.26 millionViewN/AView Earnings Details
3/7/2018Q4 2017($0.0820)($0.08)$0.30 million$0.17 millionViewN/AView Earnings Details
11/6/2017Q3 2017($0.1220)($0.10)$0.20 million$0.16 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.1070)($0.14)$0.20 million$0.19 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.0970)($0.10)$0.20 million$0.38 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.11)$0.01$0.32 million$15.28 millionViewN/AView Earnings Details
10/28/2016Q3($0.1130)($0.10)$0.30 million$0.32 millionViewN/AView Earnings Details
8/2/2016Q216($0.11)($0.11)$0.30 million$0.30 millionViewN/AView Earnings Details
5/9/2016Q1($0.11)($0.11)$0.20 million$0.29 millionViewListenView Earnings Details
3/10/2016Q4($0.11)($0.10)$0.03 million$0.19 millionViewN/AView Earnings Details
11/6/2015Q315($0.11)($0.10)$0.02 millionViewN/AView Earnings Details
8/6/2015Q215($0.11)($0.11)$0.01 millionViewN/AView Earnings Details
5/11/2015Q1($0.11)($0.12)$0.03 million$0.03 millionViewN/AView Earnings Details
3/12/2015Q414($0.11)($0.14)$0.03 millionViewN/AView Earnings Details
11/7/2014Q314($0.11)($0.11)$0.03 millionViewListenView Earnings Details
8/12/2014Q214($0.09)($0.10)$0.04 millionViewListenView Earnings Details
5/13/2014Q114($0.08)($0.12)ViewListenView Earnings Details
3/13/2014Q4($0.08)($0.10)ViewListenView Earnings Details
11/14/2013Q3($0.11)($0.11)$0.03 million$0.0070 millionViewListenView Earnings Details
8/15/2013Q213($0.12)($0.15)$0.03 millionViewN/AView Earnings Details
5/15/2013Q113($0.19)($0.15)ViewN/AView Earnings Details
3/11/2013Q4 2012($0.24)ViewN/AView Earnings Details
11/12/2012Q312($0.17)ViewN/AView Earnings Details
8/9/2012Q2 2012($0.15)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.26)($0.22)ViewN/AView Earnings Details
3/14/2012Q4 2011($0.21)($0.40)ViewN/AView Earnings Details
11/9/2011Q3 2011($0.20)($0.20)ViewN/AView Earnings Details
8/5/2011Q2 2011($0.25)($0.23)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.20)($0.25)ViewN/AView Earnings Details
3/10/2011Q4 2010($0.24)($0.22)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.06)($0.18)ViewN/AView Earnings Details
8/5/2010Q2 2010$0.02($0.23)ViewN/AView Earnings Details
5/4/2010Q1 2010($0.01)($0.08)ViewN/AView Earnings Details
3/10/2010Q4 2009$0.17ViewN/AView Earnings Details
8/4/2009Q2 2009($0.01)$0.16ViewN/AView Earnings Details
5/6/2009Q1 2009$0.01($0.01)ViewN/AView Earnings Details
3/11/2009Q4 2008$0.01$0.02ViewN/AView Earnings Details
11/6/2008Q3 2008($0.03)$0.08ViewN/AView Earnings Details
8/1/2008Q2 2008($0.09)$0.05ViewN/AView Earnings Details
5/12/2008Q1 2008$0.39($0.10)ViewN/AView Earnings Details
3/4/2008Q4 2007($0.18)($0.21)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Idera Pharmaceuticals (NASDAQ:IDRA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Idera Pharmaceuticals (NASDAQ IDRA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.42%
Institutional Ownership Percentage: 42.47%
Insider Trading History for Idera Pharmaceuticals (NASDAQ:IDRA)
Institutional Ownership by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)

Idera Pharmaceuticals (NASDAQ IDRA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/17/2018Invest Corp PillarMajor ShareholderSell200,000$2.40$480,000.00View SEC Filing  
12/15/2017Invest Corp PillarMajor ShareholderSell2,300,000$1.96$4,508,000.00View SEC Filing  
12/13/2017Invest Corp PillarMajor ShareholderSell1,100,000$1.93$2,123,000.00View SEC Filing  
10/26/2017Bros. Advisors Lp BakerDirectorBuy8,000,000$1.50$12,000,000.00View SEC Filing  
5/1/2017Invest Corp PillarDirectorSell450,815$2.26$1,018,841.90View SEC Filing  
4/25/2017Invest Corp PillarDirectorSell1,328,422$2.29$3,042,086.38View SEC Filing  
4/24/2017Invest Corp PillarDirectorSell437,829$2.29$1,002,628.41View SEC Filing  
10/7/2016Julian BakerDirectorBuy3,250,000$2.00$6,500,000.00View SEC Filing  
10/3/2016Maxine GowenDirectorBuy4,102$2.56$10,501.1210,543View SEC Filing  
5/13/2016James A GeraghtyDirectorBuy10,000$1.34$13,400.00425,649View SEC Filing  
5/12/2016Mark J CaseyVPBuy34,450$1.44$49,608.0034,450View SEC Filing  
3/15/2016Vincent MilanoCEOBuy40,000$1.97$78,800.00246,527View SEC Filing  
2/13/2015Julian BakerDirectorBuy5,333,333$3.75$19,999,998.75View SEC Filing  
12/16/2014Youssef El ZeinDirectorSell100,000$3.68$368,000.00View SEC Filing  
12/12/2014Vincent MilanoCEOBuy200,000$4.00$800,000.00View SEC Filing  
5/27/2014James A GeraghtyDirectorBuy10,000$2.65$26,500.00View SEC Filing  
12/6/2013James A GeraghtyDirectorBuy40,000$2.72$108,800.00View SEC Filing  
9/16/2013James A GeraghtyDirectorBuy60,000$1.90$114,000.00View SEC Filing  
8/19/2013James A GeraghtyDirectorBuy300,000$1.75$525,000.00View SEC Filing  
5/7/2013C Keith HartleyDirectorBuy90,000$0.49$44,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Idera Pharmaceuticals (NASDAQ IDRA) News Headlines

Source:
DateHeadline
Form 8-K IDERA PHARMACEUTICALS, For: May 18Form 8-K IDERA PHARMACEUTICALS, For: May 18
www.streetinsider.com - May 24 at 9:25 AM
Idera Pharma (IDRA) Discloses Pact with Bristol-Myers SquibbIdera Pharma (IDRA) Discloses Pact with Bristol-Myers Squibb
www.streetinsider.com - May 24 at 9:25 AM
ValuEngine Upgrades Idera Pharmaceuticals (IDRA) to "Hold"ValuEngine Upgrades Idera Pharmaceuticals (IDRA) to "Hold"
www.americanbankingnews.com - May 18 at 11:20 PM
Options Traders Expect Huge Moves in Idera Pharmaceuticals (IDRA) StockOptions Traders Expect Huge Moves in Idera Pharmaceuticals (IDRA) Stock
www.zacks.com - May 18 at 10:30 AM
Should You Be Concerned With Idera Pharmaceuticals Inc’s (NASDAQ:IDRA) -74.83% Earnings Drop?Should You Be Concerned With Idera Pharmaceuticals Inc’s (NASDAQ:IDRA) -74.83% Earnings Drop?
finance.yahoo.com - May 18 at 10:30 AM
Idera Pharmaceuticals (IDRA) Upgraded at BidaskClubIdera Pharmaceuticals (IDRA) Upgraded at BidaskClub
www.americanbankingnews.com - May 17 at 5:47 PM
IDRA May 2018 1.000 callIDRA May 2018 1.000 call
finance.yahoo.com - May 17 at 4:40 PM
Zacks Investment Research Downgrades Idera Pharmaceuticals (IDRA) to SellZacks Investment Research Downgrades Idera Pharmaceuticals (IDRA) to Sell
www.americanbankingnews.com - May 16 at 3:45 PM
Idera Pharmaceuticals (IDRA) Posts Quarterly  Earnings Results, Misses Expectations By $0.01 EPSIdera Pharmaceuticals (IDRA) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 10 at 9:53 PM
Idera Pharmaceuticals (IDRA) Buy Rating Reaffirmed at HC WainwrightIdera Pharmaceuticals' (IDRA) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - May 10 at 5:54 PM
Institutional Top Ideas Series: Ra Capital ManagementInstitutional Top Ideas Series: Ra Capital Management
seekingalpha.com - May 10 at 9:28 AM
Idera Pharmaceuticals (IDRA) Upgraded to Hold at Zacks Investment ResearchIdera Pharmaceuticals (IDRA) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:57 PM
Idera Pharmaceuticals misses by $0.01, beats on revenueIdera Pharmaceuticals misses by $0.01, beats on revenue
seekingalpha.com - May 9 at 9:15 AM
Idera: 1Q Earnings SnapshotIdera: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:15 AM
Idera Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate UpdateIdera Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 9:15 AM
Idera Pharmaceuticals (IDRA) Upgraded at ValuEngineIdera Pharmaceuticals (IDRA) Upgraded at ValuEngine
www.americanbankingnews.com - May 4 at 12:41 AM
BioCryst lands European approval for flu treatmentBioCryst lands European approval for flu treatment
finance.yahoo.com - May 2 at 9:05 AM
Idera Pharmaceuticals Announces Acceptance of Several Abstracts related to the ILLUMINATE Tilsotolimod Clinical Development Program at the American Society of Clinical Oncology (ASCO) MeetingIdera Pharmaceuticals Announces Acceptance of Several Abstracts related to the ILLUMINATE Tilsotolimod Clinical Development Program at the American Society of Clinical Oncology (ASCO) Meeting
finance.yahoo.com - April 26 at 9:11 AM
Idera Pharmaceuticals (IDRA) Lifted to "Hold" at ValuEngineIdera Pharmaceuticals (IDRA) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - April 18 at 4:44 PM
Active-Investors: Blog Exposure - Idera Pharma Announces Clinical Development Support Agreement with Pillar Partners FoundationActive-Investors: Blog Exposure - Idera Pharma Announces Clinical Development Support Agreement with Pillar Partners Foundation
www.finanznachrichten.de - April 18 at 9:36 AM
Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125
www.nasdaq.com - April 17 at 9:22 AM
Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkpoint Inhibitors at the American Association for Cancer Research (AACR) 2018 Annual MeetingIdera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkpoint Inhibitors at the American Association for Cancer Research (AACR) 2018 Annual Meeting
finance.yahoo.com - April 17 at 9:22 AM
Pillar Partners to provide funding for up to three Investigator Initiated Clinical TrialsPillar Partners to provide funding for up to three Investigator Initiated Clinical Trials
globenewswire.com - April 16 at 9:35 AM
Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125 beyond PD-1 Refractory MelanomaIdera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125 beyond PD-1 Refractory Melanoma
finance.yahoo.com - April 16 at 9:35 AM
Idera Pharmaceuticals (IDRA) Rating Increased to Hold at Zacks Investment ResearchIdera Pharmaceuticals (IDRA) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 2:14 PM
[$$] Activist Starboard Value Looks Into Forest City Realty[$$] Activist Starboard Value Looks Into Forest City Realty
finance.yahoo.com - April 6 at 4:46 PM
Idera Pharmaceuticals (IDRA) Cut to Strong Sell at ValuEngineIdera Pharmaceuticals (IDRA) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - April 6 at 11:38 AM
Why another BioCryst shareholder plans to vote against Idera mergerWhy another BioCryst shareholder plans to vote against Idera merger
finance.yahoo.com - April 3 at 4:40 PM
RA Capital Management Opposes BioCryst Pharmaceuticals Proposed Merger with Idera PharmaceuticalsRA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger with Idera Pharmaceuticals
finance.yahoo.com - April 2 at 4:43 PM
Idera Pharmaceuticals, Inc. (IDRA) Given Average Recommendation of "Hold" by BrokeragesIdera Pharmaceuticals, Inc. (IDRA) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 1 at 3:26 AM
Idera Pharmaceuticals (IDRA) Now Covered by HC WainwrightIdera Pharmaceuticals (IDRA) Now Covered by HC Wainwright
www.americanbankingnews.com - March 31 at 8:16 PM
Idera Pharmaceuticals Inc (IDRA) Short Interest UpdateIdera Pharmaceuticals Inc (IDRA) Short Interest Update
www.americanbankingnews.com - March 30 at 3:38 AM
Idera Pharmaceuticals (IDRA) Downgraded by BidaskClubIdera Pharmaceuticals (IDRA) Downgraded by BidaskClub
www.americanbankingnews.com - March 29 at 11:28 AM
Idera Pharmaceuticals (IDRA) Raised to "Strong-Buy" at BidaskClubIdera Pharmaceuticals (IDRA) Raised to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - March 28 at 12:34 AM
Idera Pharmaceuticals (IDRA) Downgraded by Zacks Investment Research to HoldIdera Pharmaceuticals (IDRA) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 27 at 10:56 PM
Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals ... - GlobeNewswire (press release)Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals ... - GlobeNewswire (press release)
globenewswire.com - March 24 at 8:19 AM
Idera Pharmaceuticals (IDRA) Lifted to "Sell" at ValuEngineIdera Pharmaceuticals (IDRA) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - March 23 at 10:46 PM
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare ConferenceBioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 22 at 4:52 PM
BioCryst launches trial of drug at center of planned merger - Triangle Business JournalBioCryst launches trial of drug at center of planned merger - Triangle Business Journal
www.bizjournals.com - March 17 at 4:49 PM
Head-To-Head Survey: Idera Pharmaceuticals (IDRA) & Immutep (IMMP)Head-To-Head Survey: Idera Pharmaceuticals (IDRA) & Immutep (IMMP)
www.americanbankingnews.com - March 17 at 1:02 AM
Idera Pharmaceuticals (IDRA) Downgraded by Zacks Investment Research to "Sell"Idera Pharmaceuticals (IDRA) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - March 10 at 12:30 AM
HC Wainwright Reiterates "$4.00" Price Target for Idera Pharmaceuticals (IDRA)HC Wainwright Reiterates "$4.00" Price Target for Idera Pharmaceuticals (IDRA)
www.americanbankingnews.com - March 9 at 7:31 PM
Idera Pharmaceuticals (IDRA) Posts Quarterly  Earnings ResultsIdera Pharmaceuticals (IDRA) Posts Quarterly Earnings Results
www.americanbankingnews.com - March 8 at 9:58 AM
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate UpdateIdera Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 7 at 9:49 AM
Idera reports 4Q lossIdera reports 4Q loss
finance.yahoo.com - March 7 at 9:49 AM
Idera Pharmaceuticals Inc (IDRA) Given Consensus Rating of "Buy" by AnalystsIdera Pharmaceuticals Inc (IDRA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 7 at 3:44 AM
Idera Pharmaceuticals (IDRA) Downgraded to "Strong Sell" at ValuEngineIdera Pharmaceuticals (IDRA) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 4 at 4:28 PM
Idera Pharmaceuticals Inc (IDRA) Position Reduced by Broadfin Capital LLCIdera Pharmaceuticals Inc (IDRA) Position Reduced by Broadfin Capital LLC
www.americanbankingnews.com - March 3 at 4:53 AM
BioCryst, Idera outline specifics on merger valueBioCryst, Idera outline specifics on merger value
finance.yahoo.com - February 26 at 9:37 AM
Idera Pharmaceuticals (IDRA) versus Oramed Pharmaceuticals (ORMP) Head-To-Head ContrastIdera Pharmaceuticals (IDRA) versus Oramed Pharmaceuticals (ORMP) Head-To-Head Contrast
www.americanbankingnews.com - February 22 at 1:50 PM

SEC Filings

Idera Pharmaceuticals (NASDAQ:IDRA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Idera Pharmaceuticals (NASDAQ:IDRA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Idera Pharmaceuticals (NASDAQ IDRA) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.